Arcutis to Present at Upcoming Investor Conference
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a biopharmaceutical company specializing in immuno-dermatology, will participate in the upcoming Cowen 42nd Annual Health Care Conference on March 7, 2022. The fireside chat is scheduled for 2:50 p.m. EST. Interested investors can access the webcast via the Events section of the company's website.
Arcutis focuses on innovative treatments for immune-mediated dermatological diseases, currently advancing multiple clinical programs and has one NDA under FDA review.
- None.
- None.
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.
Details for the company’s participation are as follows:
- Cowen 42nd Annual Health Care Conference (Virtual)
Fireside Chat Date: Monday, March 7, 2022
Fireside Chat Time: 2:50 p.m. EST
Webcasts for this conference may be accessed at the “Events” section of the Company’s website. The replay of the webcast will be available on the Arcutis website for 90 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions, with one NDA under review with the FDA and three Phase 3 clinical data readouts anticipated by the end of 2022. The company’s lead program, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis of the body and scalp, atopic dermatitis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking" statements. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
asheldon@arcutis.com
Investors
Eric McIntyre, Head of Investor Relations
emcintyre@arcutis.com
FAQ
When is Arcutis Biotherapeutics participating in the Cowen 42nd Annual Health Care Conference?
What time is the Arcutis fireside chat at the Cowen conference?
Where can I access the Arcutis conference webcast?
What is the focus of Arcutis Biotherapeutics?
What clinical developments is Arcutis currently pursuing?
